Homepage Top Section2

The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small

The late-stage trial met both the co-primary endpoints, with Nucala added to standard of care delivering statistically significant improvements in the size of nasal polyps at week 52

Novartis will work with Incyte to begin a phase III clinical study to assess the application of Jakavi to treat cytokine storm, a type of severe immune overreaction

Novellus’ patented process applies exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules for the creation of induced pluripotent stem cells (iPSCs). The iPSCs will be used to create

The parties, which have signed a partnership and license agreement, have agreed to discover, develop, manufacture, and commercialise fully human neutralising monoclonal antibodies to address the COVID-19 pandemic.

The company has initiated an additional research and development project targeting the coronavirus group and has wrapped up initial screening under the repurposed and new drug discovery platform

Zolgensma also delivered the desired results in patients who were given presymptomatic treatment and also in certain participants aged over five years. The gene therapy could sustain durability

Feinstein Institutes researchers have collaborated with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to detect efficient treatments for patients currently hospitalised in moderate and severe conditions with COVID-19. The

Compared to traditional vaccines, the DNA-based vaccine will directly induce a plasmid for encoding the antigen against which an immune response is required and depends on the production